Physician profile
Paula A Mitchell
NPI 1205110582
$8,298.39
in general payments reported to CMS, 2019-2025
46 companies · $215 in 2025
The $215 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,778 · 2022: $3,045 · 2023: $1,684 · 2024: $577 · 2025: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,456 · Education: $19.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,455.93 |
| Education | $19.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $1,106.63 | 2021-2024 | Dexcom G6 Transmitter |
| Amgen INC. | $983.65 | 2021-2023 | Prolia, Tavneos, Evenity |
| Novo Nordisk INC | $751.88 | 2021-2022 | |
| Abbott Laboratories | $740.03 | 2021-2025 | Freestyle Libre 3, Freestyle Libre |
| Astrazeneca Pharmaceuticals Lp | $678.15 | 2021-2024 | Farxiga |
| Lilly USA, LLC | $373.04 | 2021-2024 | Jardiance |
| Medtronic, INC. | $290.06 | 2021-2024 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $266.72 | 2021-2023 | Ofev |
| Aurinia Pharma U.S., INC. | $248.03 | 2021-2024 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $232.30 | 2022-2023 | |
| Esperion Therapeutics, INC. | $215.46 | 2021-2022 | |
| Radius Health, INC. | $202.21 | 2021-2024 | Tymlos |
| Alexion Pharmaceuticals, INC. | $186.66 | 2021-2023 | Strensiq |
| Coloplast Corp | $183.53 | 2022 | |
| Sanofi-Aventis U.S. LLC | $175.26 | 2021-2023 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $148.53 | 2021-2023 | Steglujan, Steglatro, Segluromet |
| Corcept Therapeutics | $127.53 | 2022-2024 | Korlym |
| Xeris Pharmaceuticals, INC. | $121.56 | 2022-2024 | Recorlev |
| Janssen Biotech, INC. | $110.02 | 2021-2023 | Tremfya |
| Antares Pharma, INC. | $106.53 | 2021-2023 | Tlando, Xyosted |
| Amarin Pharma, INC. | $89.68 | 2021-2022 | |
| Insulet Corporation | $86.53 | 2024 | Omnipod |
| Beta Bionics, INC. | $85.47 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Novartis Pharmaceuticals Corporation | $74.08 | 2023-2025 | |
| Sobi, INC | $70.06 | 2022-2023 | |
| Atricure, INC. | $68.24 | 2025 | Atriclip Laa Exclusion System, Atricure Cryoice Cryosphere Cryoablation System, Synergy Ablation System |
| Ucb, INC. | $66.73 | 2022-2024 | Cimzia |
| Abbvie INC. | $65.57 | 2021-2023 | |
| Mallinckrodt Hospital Products INC. | $52.77 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $46.25 | 2023-2024 | Purified Cortrophin Gel |
| Ibsa Pharma INC. | $42.56 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.46 | 2021-2022 | |
| Clarus Therapeutics INC. | $35.54 | 2021 | |
| Recordati_rare_diseases_inc. | $31.29 | 2021-2024 | Signifor Lar, Isturisa |
| Pfizer INC. | $21.68 | 2023 | |
| Celltrion USA INC. | $19.97 | 2023 | Yuflyma |
| Vivus LLC | $19.50 | 2021 | |
| Acella Pharmaceuticals, LLC | $18.25 | 2023 | NP Thyroid 60 |
| Ipsen Biopharmaceuticals, INC | $17.89 | 2022 | |
| Kyowa Kirin, INC. | $16.92 | 2024 | Crysvita |
| Zealand Pharma US, INC. | $16.90 | 2021 | |
| Horizon Therapeutics Plc | $15.70 | 2021 | |
| Amneal Pharmaceuticals LLC | $13.56 | 2023 | Unithroid |
| Cumberland Pharmaceuticals, INC. | $13.04 | 2022 | |
| Kiniksa Pharmaceuticals, Ltd. | $12.93 | 2023 | Arcalyst |
| Takeda Pharmaceuticals U.S.A., INC. | $11.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.